01 — At a Glance
The Pharma Company That Got Burned (& Not in the Good Way)
- 52-Week High / Low₹2,725 / ₹1,764
- Q3 FY26 Revenue₹180 Cr
- Q3 FY26 PAT₹22.5 Cr
- Q3 EPS₹13.38
- Annualised EPS (Q3×4)₹53.5
- Book Value₹335
- Price to Book5.65x
- Dividend Yield1.05%
- Debt / Equity0.00x
- 3yr Profit CAGR31.5%
Auditor’s Opening Note: RPG Life Sciences closed Q3 FY26 with ₹180 crore revenue (+4.2% QoQ) and ₹22.5 crore PAT—a -18.3% YoY decline thanks to a manufacturing fire incident at the API facility in Navi Mumbai back in January 2025. But here’s the thing: the company is debt-free, boasts 32.8% ROCE, generates consistent profits, and recently created a ₹105 crore WhatsApp— wait, Wholly Owned Subsidiary (WOS) to spin out the API business by March 2026. This is either genius restructuring or corporate chaos. Your money, your call.
02 — Introduction
The Mid-Sized Pharma Darling That Keeps Surprising You
RPG Life Sciences is what happens when a 45-year-old successful industrialist (Harsh Vardhan Goenka) decides: “You know what? Pharma is cool. Let me build this.” The result? A modestly scaled, debt-free pharmaceutical company with leadership positions in niche therapies—immunosuppressants, gastroenterology, nephrology, rheumatology, oncology, pain management—the whole shebang.
Three manufacturing facilities. Approvals from WHO, EU GMP, TGA Australia, PMDA Japan. 100,000+ doctors on their digital platform (RPG Serv). Strong brands like Azoran, Naprosyn, Lomotil, Aldactone. And revenues that have grown at 12% CAGR over the past 5 years while maintaining 20-25% operating margins like clockwork. Boring? Yes. Profitable? Absolutely.
Then came January 2025, when a fire incident at their Navi Mumbai API facility decided to crash the Q4 FY25 party. Loss insured at ₹16.33 crore. A new CEO appointment in November 2024 (Ashok Nair replaces Yugal Sikri, who retired after 7 years). CFO Vishal Shah resigned in October 2025, only to be replaced immediately. And now—December 2025—they’re spinning out the entire API business into a separate WOS with ₹105 crore capex and a handoff by March 31, 2026. This is not your grandmother’s pharmaceutical company; this is your grandmother’s pharmaceutical company after three espressos and a life coach consultation.
Concall Reality Check (Jan 2026): Management explicitly stated they are “focused on execution” across 10 parallel transformation projects. Nobody sounded panicked. Everyone sounded tired. This is peak corporate India—multiple fires burning, literally and figuratively, handled with the calm of a Delhi auto-driver during monsoon traffic.
03 — Business Model: Boring by Design
Three Simple Bets: India, Emerging Markets, and Specialty Molecules
RPG Life Sciences runs three buses and hopes they don’t crash simultaneously (spoiler: one did, temporarily). The bus model: Domestic Formulations (DF), International Formulations (IF), and Active Pharma Ingredients (APIs).
Domestic Formulations (66% of FY25 revenue, ₹429 Cr): Branded drugs for Indian patients. Strong market share in niche spaces. Azoran (immunosuppressant), Naprosyn (pain management), Lomotil (gastroenterology), Aldactone (cardiac + nephrology). Growing new portfolio in oncology, rheumatology, chronic diseases. Distribution through 1 lakh+ doctors, sales force at 6.5 lakh PCPM (Per Core Per Month productivity—fancy way of saying their salespeople are reasonably efficient).
International Formulations (18% of FY25 revenue, ₹118 Cr): Generic and branded generics for regulated (Canada, Europe, Australia) and emerging markets (Southeast Asia, Africa, Latin America). Smaller scale but high-margin international play. New customer addition pipeline and market expansion are supposedly on track, though the fire incident affected manufacturing temporarily.
APIs (16% of FY25 revenue, ₹90.2 Cr): High-value synthetic active pharmaceutical ingredients. Backward integration play supporting the formulations business. Now getting spun out into a separate WOS—more on that later. The Navi Mumbai facility handles immunosuppressants, which is a big deal for competitive advantage and supply chain resilience.
The business model is straightforward: develop brands, patent-protected or market-differentiated drugs, control costs, generate consistent 20-25% operating margins, and return cash to shareholders. It’s not GLAMOROUS. It’s not a “growth story” that’ll make a TED speaker sweat. It’s just… steady. Like a ’90s Honda Civic—reliable, boring, and you know exactly what you’re getting.
Debt-to-Equity0.00xAlways. Zero Debt.
ROCE32.8%Returns > Cost of Capital
ROE 3yr Avg25.2%Solid Equity Returns
OPM Avg22-25%Stable Margins
🔴 The Fire Incident (Jan 3, 2025): Manufacturing plant at Navi Mumbai caught fire. API segment took a hit. Loss insured at ₹16.33 crore. Expected insurance recovery: ₹16.33 crore. Actual operational impact: temporary capacity loss at one of the three units. The concall in January 2026 barely mentioned it—which means either (a) it’s ancient history, or (b) management is playing it very cool.
💬 Real talk: Would you trust a pharma company with a fire incident in their API plant? Or does the debt-free balance sheet and insurance coverage give you confidence? Tell us what keeps you up at night.
04 — Financials Overview
Q3 FY26: The Numbers (Minus the Fire)
Result type: Quarterly Results | Q3 FY26 EPS: ₹13.38 | Annualised EPS (Q3×4): ₹53.52 | FY25 Full-Year EPS: ₹110.79 (excluding exceptional items)
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 180.0 | 172.7 | 182.0 | +4.2% | -1.1% |
| Operating Profit | 40.0 | 46.9 | 39.0 | -14.7% | +2.6% |
| OPM % | 22% | 27% | 21% | -500 bps | +100 bps |
| PAT | 22.5 | 27.5 | 23.0 | -18.3% | -2.2% |
| EPS (₹) | 13.38 | 16.40 | 13.90 | -18.3% | -3.7% |
What Happened Here: Q3 FY26 revenue grew 4.2% YoY from ₹172.7 Cr to ₹180 Cr—respectable but not spectacular. Operating margin compressed from 27% to 22% (-500 bps YoY), and PAT declined 18.3% YoY. The big culprit? The Navi Mumbai API facility fire incident which impacted Q4 FY25 and continued to pressure Q3 FY26 margins. But wait—there’s a catch. The FY25 full-year EPS of ₹110.79 EXCLUDED exceptional items (the insurance recovery and land asset sale gain of ₹83 crore). Current P/E at 29.8x is calculated on TTM earnings including those exceptional items. If you strip out one-time gains, the “normal” earnings are much lower, and the P/E is actually north of 35x on core operations. That’s a red flag worth sticking around for.
05 — Valuation: Fair Value Range
Is 29.8x P/E Justified? (Spoiler: Probably Not)
